Literature DB >> 3284898

In vitro method to differentiate isolates of type III Streptococcus agalactiae from symptomatic and asymptomatic patients.

J J Maurer1, S J Mattingly.   

Abstract

Streptococcus agalactiae (group B streptococci) isolates from infected infants have been demonstrated to have three- to fourfold or higher levels of cell-associated lipoteichoic acid than isolates from asymptomatically colonized infants, suggesting a role for this cell surface polymer in the relative virulence of these organisms. The present study indicates that symptomatic isolates of type III group B streptococci can be readily differentiated from asymptomatic strains by their response to various levels of phosphate in a chemically defined medium (FMC). Both classes of isolates had the same doubling time (TD of 30 to 35 min) in FMC containing 65 mM sodium phosphate. However, levels of phosphate greater than 125 mM distinguished the two classes of strains. Asymptomatic strains pregrown in 65 mM phosphate to the stationary phase rapidly initiated growth at elevated phosphate levels, while symptomatic strains initiated growth only after a prolonged incubation period (greater than 400 min). These results suggest that the physiological growth response of clinical isolates of group B streptococci to phosphate can serve as a diagnostic aid in screening potentially virulent strains in pregnant women and newborn infants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284898      PMCID: PMC266412          DOI: 10.1128/jcm.26.4.686-691.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids.

Authors:  D AMINOFF
Journal:  Biochem J       Date:  1961-11       Impact factor: 3.857

2.  Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci.

Authors:  T W Milligan; C J Baker; D C Straus; S J Mattingly
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

3.  Growth and amino acid requirements of various strains of group B streptococci.

Authors:  T W Milligan; T I Doran; D C Straus; S J Mattingly
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

4.  Growth of several cariogenic strains of oral streptococci in a chemically defined medium.

Authors:  B Terleckyj; N P Willett; G D Shockman
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

5.  Biosynthetic capacity for type-specific antigen synthesis determines the virulence of serotype III strains of group B streptococci.

Authors:  M K Yeung; S J Mattingly
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Role of cellular lipoteichoic acids in mediating adherence of serotype III strains of group B streptococci to human embryonic, fetal, and adult epithelial cells.

Authors:  T J Nealon; S J Mattingly
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

7.  Biosynthesis of D-alanyl-lipoteichoic acid in Lactobacillus casei: D-alanyl-lipophilic compounds as intermediates.

Authors:  V M Brautigan; W C Childs; F C Neuhaus
Journal:  J Bacteriol       Date:  1981-04       Impact factor: 3.490

8.  Kinetic and chemical analyses of the biologic significance of lipoteichoic acids in mediating adherence of serotype III group B streptococci.

Authors:  T J Nealon; S J Mattingly
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

9.  Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model.

Authors:  D L Durham; S J Mattingly; T I Doran; T W Milligan; D C Straus
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  7 in total

1.  High-virulence clone of group B streptococci unable to grow at high temperatures is present in serotypes other than type III.

Authors:  Gerardo C Palacios; Maria N Gonzalez; Magdalena Beltran; Jose L Arredondo; Javier Torres; Fortino Solorzano
Journal:  Curr Microbiol       Date:  2006-12-13       Impact factor: 2.188

2.  Identification of a high-virulence clone of serotype III Streptococcus agalactiae by growth characteristics at 40 degrees C.

Authors:  S J Mattingly; J J Maurer; E K Eskew; F Cox
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

3.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Prophagic DNA fragments in Streptococcus agalactiae strains and association with neonatal meningitis.

Authors:  Nathalie van der Mee-Marquet; Anne-Sophie Domelier; Laurent Mereghetti; Philippe Lanotte; Agnès Rosenau; Willem van Leeuwen; Roland Quentin
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Sialic acid levels and lag time of growth in chemically defined medium containing 200 mM phosphate among strains of various serotypes of Streptococcus agalactiae.

Authors:  Y Nagano; N Nagano; S Takahashi; A Suzuki; Y Okuwaki
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

6.  Screening of type Ia and Ib Streptococcus agalactiae strains with high sialic acid levels by determination of susceptibility to tetracyclines.

Authors:  Y Nagano; N Nagano; S Takahashi; A Suzuki; Y Okuwaki
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

7.  Visualization of the role of host heme on the virulence of the heme auxotroph Streptococcus agalactiae.

Authors:  Laetitia Joubert; Jean-Baptiste Dagieu; Annabelle Fernandez; Aurélie Derré-Bobillot; Elise Borezée-Durant; Isabelle Fleurot; Alexandra Gruss; Delphine Lechardeur
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.